Johnson & Johnson Ends Partnership With Bavarian Nordic on Hepatitis B and HPV Vaccines

On May 9, Johnson & Johnson announced that it had terminated its partnership and licensing agreement with Bavarian Nordic. The main content of the agreement is to use Bavarian Nordic's MVA-BN technology to develop potential vaccines against hepatitis B virus and human papilloma virus. Currently, J&J has not used the technology to develop a hepatitis B vaccine.

For hepatitis B, Johnson & Johnson will continue to prioritize the use of its technology platform to develop related therapeutic drugs. Because hepatitis B remains a serious health problem, about 296 million people worldwide are affected by the disease, and nearly 900,000 people die from it every year.

For human papillomavirus, J&J does not intend to focus its research on its therapeutic vaccine, as preventive vaccines are already widely used.

However, J&J's collaboration with the company on HIV and Ebola is still ongoing.